** Shares of China Medical System Holdings 0867.HK rise 4% to HK$8.54, their highest since February 27
** Stock set for the biggest one-day rise since February 26; on track for fourth straight session of gains
** The Chinese medicine producer says China's National Medical Products Administration has granted drug clinical trials approval to its Cardiac Myosin Inhibitor CMS-D003, which is a targeted therapy for hypertrophic cardiomyopathy
** Co, with market capitaliation of HK$20.64 bln ($2.66 bln), says CMS-D003 can also be developed for the treatment of heart failure with preserved ejection fraction in the future
** Hong Kong's healthcare index .HSCIH and Hang Seng Index .HSI both slip 0.7%
** Stock up 8.7% YTD
($1 = 7.7713 Hong Kong dollars)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。